JeniaJenab-WolcottMD

Oncology • Camden, NJ

Physician

Join to view full profile

Dr. Jenab-Wolcott is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jenab-Wolcott's full profile

Already have an account?

Office
2 Cooper Plz
Camden, NJ 08103
Phone+1 855-632-2667

Fax+1 302-738-5917

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2007 - 2010
Yale-New Haven Medical CenterResidency, Internal Medicine, 2003 - 2006
Tufts University School of MedicineClass of 2003

Certifications & Licensure

MD State Medical License 2013 - 2026
NY State Medical License 2024 - 2026
DE State Medical License 2013 - 2025
NJ State Medical License 2013 - 2025
PA State Medical License 2007 - 2024
CT State Medical License 2006 - 2020
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Start of enrollment: 2011 Jan 01
Terminated
Phase 3

Publications & Presentations

PubMed

37 citations
p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells.
Indira Unnikrishnan, Arash Radfar, Jenia Jenab-Wolcott, Naomi Rosenberg
Molecular and Cellular Biology. 1999-07-01
51 citations
Bevacizumab: current indications and future development for management of solid tumors
Jenia Jenab-Wolcott, Bruce J. Giantonio
Expert Opinion on Biological Therapy. 2009-04-03
8 citations
The absence of Msh2 alters abelson virus pre-B-cell transformation by influencing p53 mutation.
Jenia Jenab-Wolcott, Daniel Rodriguez-Correa, Armin Reitmair, Tak W. Mak, Naomi Rosenberg
Molecular and Cellular Biology. 2000-11-15